Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7850927 | 0.83 | TSHR (0.48) | TSHRHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL6755569 | 0.82 | DGAT1 (0.39) | TSHRALDH1A1KCNN4THRBKMT2A | |
| SCHEMBL161711 | 0.78 | NAALAD2 (0.45) | NAALAD2TSHRCYP2C9HIF1AHSD17B10 | |
| SCHEMBL29184392 | 0.78 | ELANE (0.37) | TSHRHSD17B10ALDH1A1CYP3A4KCNN4 | |
| SCHEMBL25325252 | 0.78 | HMGCR (0.42) | TSHRHIF1AALDH1A1KCNN4KMT2A | |
| Hydrochloric Acid SCHEMBL9429165 | 0.77 | NAALAD2 (0.44) | NAALAD2TSHRCYP2C9HIF1AHSD17B10 | |
| SCHEMBL7964223 | 0.77 | NAALAD2 (0.44) | NAALAD2TSHRCYP2C9HIF1AHSD17B10 | |
| SCHEMBL3502125 | 0.75 | — | — | |
| SCHEMBL9620420 | 0.73 | TSHR (0.47) | TSHRHSD17B10ALDH1A1ESR1MEN1 | |
| SCHEMBL1246632 | 0.73 | LCK (0.47) | TSHRALDH1A1KCNN4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885817-B1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIV DURHAM (GB) | 2016-05-11 | — | — | EP | disclosed |
| US-8193174-B2 | Responsive luminescent lanthanide complexes | UNIVERSITY OF DURHAM (GB) | 2012-06-05 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20080312431-A1 | Responsive Luminescent Lanthanide Complexes | UNIVERSITY OF DURHAM (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1960356-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948604-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1885817-A1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIVERSITY OF DURHAM (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006120444-A1 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES | UNIVERSITY OF DURHAM (GB) | 2006-11-16 | — | — | WO | disclosed |
| EP-0480745-A2 | Substituted dihydrothieno-thiophene-2-sulfonamides and dioxides thereof | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G4A, PLA2G1B, PLA2G4B | NAALAD2 218/4885TSHR 2153/4885CYP2C9 2424/4885 |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | NAALAD2 1131/4885TSHR 2179/4885CYP2C9 407/4885 |
| US-20080312431-A1 | Responsive Luminescent Lanthanide Complexes | TPR, NLRP1, NISCH | NAALAD2 2193/4885TSHR 552/4885CYP2C9 3002/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | NAALAD2 123/4885TSHR 3511/4885CYP2C9 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.